Press releases
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
- Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
- Neurocrine Biosciences to Participate at Investor Conferences in March
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
More ▼
Key statistics
On Friday, Neurocrine Biosciences Inc (NBIX:DEU) closed at 123.10, -9.08% below its 52-week high of 135.40, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 124.70 |
---|---|
High | 127.00 |
Low | 123.05 |
Bid | 123.25 |
Offer | 123.55 |
Previous close | 123.70 |
Average volume | 70.67 |
---|---|
Shares outstanding | 100.58m |
Free float | 99.31m |
P/E (TTM) | 54.51 |
Market cap | 13.33bn USD |
EPS (TTM) | 2.43 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 17:09 BST.
More ▼